
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner HAIFA, ISRAEL, July 8, 2025 /EINPresswire.com/ -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) …